After years of incompetence and BS from the previous MD and management team and weak Chairman at least we can see actually what is happening.
If (Nextstellis unit sales increase and the Dermatology improvement is maintained), in Q2, then a little confidence may come back into the stock.
I am very pleased that the CEO will concentrate on the existing business and not look to any acquisitions for the moment.
Buying back at this low share price is sensible and 15% would consume about A$40m of cash.
All in all quite a positive update.
Ann: Mayne Pharma provides update on 1Q FY24 trading and outlook, page-17
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.95 |
Change
-0.040(1.00%) |
Mkt cap ! $336.0M | |||
| Open | High | Low | Value | Volume |
| $4.08 | $4.12 | $3.95 | $277.7K | 68.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 422 | $3.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.01 | 422 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| MYX (ASX) Chart |